Vancomycin administration during dialysis with low-flux polysulfone membranes: Traditional versus a supplemental dosage regimen

American Journal of Health-System Pharmacy

Volumn 60, Issue 15, 2003, Pages 1564-1568

  Stamatakis, Mary K ^a   Schreiber, Joy M ^b   Slain, Douglas ^a   Gunel, Erdogan ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT; POLYMER; POLYSULFONE P 1700; SULFONE;

ARTICLE; DIALYSIS; DRUG DOSE REGIMEN; DRUG HALF LIFE; HUMAN; MEDICAL PRACTICE; PRIORITY JOURNAL; ARTIFICIAL MEMBRANE; BACTERIAL INFECTION; BIOASSAY; CHEMISTRY; COMPARATIVE STUDY; DRUG ADMINISTRATION; ECONOMICS; FEMALE; HALF LIFE TIME; MALE; METHODOLOGY; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; POLYMERS; RENAL DIALYSIS; SULFONES; VANCOMYCIN;

EID: 0642277763     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.15.1564     Document Type: Article

References (31)

1. Healy DP, Polk RE, Garson ML et al. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother. 1987; 31:393-7.
2. Golper TA, Noonan HM, Elzinga L et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther. 1988; 43:565-70.
3. Tan CC, Lee HS, Ti TY et al. Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure. Ther Drug Monit. 1990; 12:29-34.
4. Bastani B, Spyker DA, Minocha A et al. In vivo comparison of three different hemodialysis membranes for vancomycin clearance: cuprophan, cellulose acetate and polyacrylonitrile. Dial Transplant. 1988; 17:527-43.
5. Masur H, Francioli P, Ruddy M et al. Vancomycin serum levels and toxicity in chronic hemodialysis patients with Staphylococcus aureus bacteremia. Clin Nephrol. 1983; 20:85-8.
6. Lanese DM, Alfrey PS, Molitoris BA. Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int. 1989; 35:1409-12.
7. Torras J, Cao C, Rivas MC et al. Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylnitrile. Clin Nephrol. 1991; 36:35-41.
8. Bohler J, Reetze-Bonorden P, Keller E et al. Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes. Eur J Clin Pharmacol. 1992; 42:635-9.
9. DeSoi CA, Sahm DF, Umans JG. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis. 1992; 20:354-60.
10. Quale JM, O'Halloran JJ, DeVincenzo N et al. Removal of vancomycin by high-flux hemodialysis membranes. Antimicrob Agents Chemother. 1992; 36:1424-6.
11. Pollard TA, Lampasona V, Akkerman S et al. Vancomycin redistribution: dosing recommendations following high-flux hemodialysis. Kidney Int. 1994; 45:232-7.
12. Welage LS, Mason NA, Hoffman EJ et al. Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics. J Am Soc Nephrol. 1995; 6:1284-90.
13. Touchette MA, Patel RV, Anandan JV et al. Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease. Am J Kidney Dis. 1995; 26:469-74.
14. Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int. 1996; 50:929-36.
15. Scott MK, Macias WL, Kraus MA et al. Effects of dialysis membrane on intradialytic vancomycin administration. Pharmacotherapy. 1997; 17:256-62.
16. Zoer J, Schrander-van der Meer AM, van Dorp WT. Dosage recommendations of vancomycin during haemodialysis with highly permeable membranes. Pharm World Sci. 1997; 19:191-6.
17. Foote EF, Dreitlein WB, Steward CA et al. Pharmacokinetics of vancomycin when administered during high flux hemodialysis. Clin Nephrol 1998; 50:51-5.
18. Centers for Disease Control and Prevention. National surveillance of dialysis-associated diseases in the United States. www.cdc.gov/ncidod/hip/ Dialysis/dialysis99.pdf (accessed 2002 Mar 18).
19. Vancomycin Flex reagent cartridge/Dimension clinical chemistry system. Newark, DE: Dade Behring; 1998.
20. Smith PF, Morse GD. Accuracy of measured vancomycin serum concentrations in patients with end-stage renal disease. Ann Pharmacother. 1999; 33:1329-35.
21. Leypoldt JK, Cheung AK, Carroll CE et al. Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis. 1999; 33:349-55.
22. Keller F, Hörstensmeyer C, Looby M et al. Vancomycin dosing in haemodialysis patients and Bayesian estimate of individual pharmacokinetic parameters. Int J Artif Organs. 1994; 17:19-26.
23. Wilhelm MP, Estes L. Symposium on antimicrobial agents, part XII. Vancomycin. Mayo Clin Proc. 1999; 74:928-35.
24. Cantú TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis. 1994; 18:533-43.
25. Andrés I, López R, Pou L et al. Vancomycin monitoring: one or two serum levels? Ther Drug Monit. 1997; 19:614-9.
26. Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity: a review. Med Toxicol Adverse Drug Exp. 1988; 3:376-86.
27. Karam CM, McKinnon PS, Neuhauser MM et al. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy. 1999; 19:257-66.
28. Mulhern JG, Braden GL, O'Shea MH et al. Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am J Kidney Dis. 1995; 25:611-5.
29. Moellering RC Jr. Editorial response: staphylococci vs. glycopeptides-how much are the battle lines changing? Clin Infect Dis. 1999; 29:768-70.
30. Smith TL, Pearson ML, Wilcox KR et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999; 340: 493-501.
31. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR. 2002; 51:565-7.